Vascular Anomaly Clinical Trial
Official title:
Efficacy and Safety of Sirolimus in the Treatment of the Complicated Vascular Anomalies
NCT number | NCT03583307 |
Other study ID # | 2018-618 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 1, 2018 |
Est. completion date | February 19, 2021 |
Verified date | March 2022 |
Source | West China Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the safety and efficacy of Sirolimus in complicated vascular anomalies in Chinese children
Status | Completed |
Enrollment | 126 |
Est. completion date | February 19, 2021 |
Est. primary completion date | February 19, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 18 Years |
Eligibility | Inclusion Criteria: - All patients included in the present research must be diagnosed with one of the following vascular anomalies: 1. Kaposiform Hemangioendotheliomas without Kasabach-Merritt Phenomenon 2. Tufted Angioma without Kasabach-Merritt Phenomenon 3. Capillary Malformations 4. Lymphatic Malformations 5. Venous Malformations 6. Capillary-Venous Malformation (CVM) 7. Capillary-Lymphatic Malformation (CLM) 8. Lymphatic-Venous Malformation (LVM) 9. Capillary-Lymphatic-Venous Malformation (CLVM) 10. Multifocal Lymphangiomatosis and Thrombocytopenia (MLT) - Patients must be 0 - 18 years of age at the time of study entry. - Without functional impairment requiring treatment of corticosteroid. - Organ function requirements: - Adequate liver function Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)for age, and alanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x upper limit normal (ULN) for age. - Adequate renal function 0-5 years of age maximum serum creatinine (mg/dL) of 0.8 6-10 years of age maximum serum creatinine (mg/dL) of 1.0 11-15 years of age maximum serum creatinine (mg/dL) of 1.2 16-18 years of age maximum serum creatinine (mg/dL) of 1.5 - Adequate bone marrow function: Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter - Consent of parents (or the person having parental authority in families): Signed and dated written informed consent. Exclusion Criteria: - Allergy to sirolimus or other rapamycin analogues. - Allergy to sirolimus or other rapamycin analogues. - Any known evidence of significant local or systemic uncontrolled infection, defined as receiving intravenous antibiotics at the time of randomization. - Patients must not be known to be Human Immunodeficiency Virus positive or known immunodeficiency. Testing is not required unless a condition is suspected. - Other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study (e.g. uncontrolled diabetes, uncontrolled hypertension, severe malnutrition, chronic liver or renal disease, active upper gastrointestinal tract ulceration). - Impairment of gastrointestinal function or chronic gastrointestinal disease that may significantly alter the absorption of sirolimus. - Patients who have a history of malignancy. - Patients with an inability to participate or to follow the study treatment and assessment plan. - Patients who have a history of treatment with sirolimus or other mTOR inhibitor. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital of Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Volumetric changes in complicated vascular anomalies to sirolimus | Response to sirolimus treatment was measured by volumetric magnetic resonance imaging (MRI) analyses, which were performed at baseline and 6 and 12 months after treatment and were independently assessed by 2 radiologists. Changes in size of vascular anomalies were classified as further growth (increase of =10%), no change (<10% increase and <10% decrease), partial involution (decrease of =10% and <75%), nearly complete involution (decrease of =75% and <100%), or complete involution (100%).
Photographs of the complicated vascular anomalies were taken at months 0, 3, 6 and 12 by a medical photographer. Complete/nearly complete resolution of the vascular anomalies at month 12 compared to baseline based on the intra-patient blinded centralized independent qualitative assessments of month 12 MRI. |
Baseline, 6, and 12 months | |
Primary | The changes in the patient's symptoms and/or complications. | Baseline, 3, 6, and 12 months | ||
Secondary | Quality of Life in patients by the Pediatric Quality of Life Inventory TM (PedsQLTM) 4.0 Generic Core Scales. | The PedsQL 4.0 Generic Core Scales encompass: 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items), and were developed through focus groups and cognitive interviews. The PedsQL 4.0 Generic Core Scales are comprised of parallel child self-report (ages 5-18) and parent proxy-report formats (ages 0-18). A 5-point response scale is utilized across child self-report for ages 8 to 18 and parent proxy-report (0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; 4=almost always a problem). For patients between ages 5-7, the response scale is simplified to a 3-point scale (0=not at all a problem; 2=sometimes a problem; 4=a lot of a problem. Items are reverse-scored and linearly transformed to a 0 to 100 scale (0=100, 1=75, 2 =50, 3=25, 4=0). Scale Scores are computed as the sum of the items divided by the number of items answered. | Baseline, 6, 12 months | |
Secondary | Measuring the impact of vascular anomalies on family functioning by PedsQLTM 4.0 Family Impact Module (FIM). | Baseline, 6, 12 months | ||
Secondary | Frequency of adverse events as assessed by CTCAE v4.0 | Baseline, 3, 6, 12 months | ||
Secondary | Changes in plasma levels fibrinogen and/ or D-dimers | Baseline, 3, 6, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04194619 -
Pregnancy in Women With Rare Multisystemic Vascular Diseases: COGRare5 Study
|
||
Enrolling by invitation |
NCT00833599 -
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
|
||
Recruiting |
NCT04464655 -
A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease
|
||
Not yet recruiting |
NCT05983159 -
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
|
Phase 2 | |
Completed |
NCT04836884 -
Vascular Anomaly Pathology and Genomics Biopsy Study
|
N/A | |
Recruiting |
NCT03001180 -
Identification of Biomarkers for Patients With Vascular Anomalies
|
||
Recruiting |
NCT04172922 -
Topical Rapamycin/Sirolimus for Complicated Vascular Anomalies and Other Susceptible Lesions
|
Phase 1 |